The Centers for Medicare & Medicaid Services (CMS) has proposed a rule (CMS-4187) that will require prescription drug manufacturers to disclose in television ads the wholesale acquisition cost for Medicare or Medicaid prescription drugs.
The proposed rule is the latest in President Trump’s efforts to lower prescription drug prices and increase price transparency. Under the proposed rule, the price required to be posted would be for a typical course of treatment for an acute medication like an antibiotic, or a 30-day supply of medication for a chronic condition that is taken every month. The posting would take the form of a legible statement at the end of the ad. Prescription drugs with a list price of less than $35 per month would be exempt.
Read the policy brief on CMS-4187 and the proposed rule. Comments will be accepted until Dec. 17 and can be submitted here.
